Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab in MSI-H/dMMR Solid Tumors
NCT04547101Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Apr 2020
- Primary completion
- Sep 2022
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in solid tumor, sponsored by Akeso, Inc. Primary endpoint: Objective Response Rate up to 2 years. Started Apr 2020; status: terminated.
02
Drugs
cadonilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04547101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547101.